214 related articles for article (PubMed ID: 22829012)
1. Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas.
Johnson KJ; Fisher MJ; Listernick RL; North KN; Schorry EK; Viskochil D; Weinstein M; Rubin JB; Gutmann DH
Fam Cancer; 2012 Dec; 11(4):653-6. PubMed ID: 22829012
[TBL] [Abstract][Full Text] [Related]
2. Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1.
Johnson KJ; Zoellner NL; Gutmann DH
Cancer Epidemiol; 2016 Jun; 42():53-9. PubMed ID: 27018750
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
Amato A; Imbimbo BP; Falsini B
Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302
[TBL] [Abstract][Full Text] [Related]
4. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
Robert-Boire V; Rosca L; Samson Y; Ospina LH; Perreault S
Pediatr Neurol; 2017 Oct; 75():55-60. PubMed ID: 28847625
[TBL] [Abstract][Full Text] [Related]
5. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.
Hutter S; Piro RM; Waszak SM; Kehrer-Sawatzki H; Friedrich RE; Lassaletta A; Witt O; Korbel JO; Lichter P; Schuhmann MU; Pfister SM; Tabori U; Mautner VF; Jones DTW
Hum Genet; 2016 May; 135(5):469-475. PubMed ID: 26969325
[TBL] [Abstract][Full Text] [Related]
6. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
Freret ME; Gutmann DH
J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
[TBL] [Abstract][Full Text] [Related]
7. Optic Pathway Gliomas in Neurofibromatosis Type 1.
Campen CJ; Gutmann DH
J Child Neurol; 2018 Jan; 33(1):73-81. PubMed ID: 29246098
[TBL] [Abstract][Full Text] [Related]
8. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
Listernick R; Ferner RE; Liu GT; Gutmann DH
Ann Neurol; 2007 Mar; 61(3):189-98. PubMed ID: 17387725
[TBL] [Abstract][Full Text] [Related]
9. Associations between allergic conditions and pediatric brain tumors in Neurofibromatosis type 1.
Porcelli B; Zoellner NL; Abadin SS; Gutmann DH; Johnson KJ
Fam Cancer; 2016 Apr; 15(2):301-8. PubMed ID: 26666764
[TBL] [Abstract][Full Text] [Related]
10. Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey.
Sharafi P; Varan A; Ersoy-Evans S; Ayter S
Childs Nerv Syst; 2024 Feb; 40(2):511-515. PubMed ID: 37401974
[TBL] [Abstract][Full Text] [Related]
11. Brain gliomas, hydrocephalus and idiopathic aqueduct stenosis in children with neurofibromatosis type 1.
Glombova M; Petrak B; Lisy J; Zamecnik J; Sumerauer D; Liby P
Brain Dev; 2019 Sep; 41(8):678-690. PubMed ID: 31000370
[TBL] [Abstract][Full Text] [Related]
12. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis type 1 and sporadic optic gliomas.
Singhal S; Birch JM; Kerr B; Lashford L; Evans DG
Arch Dis Child; 2002 Jul; 87(1):65-70. PubMed ID: 12089128
[TBL] [Abstract][Full Text] [Related]
14. Improving outcomes for neurofibromatosis 1-associated brain tumors.
Brossier NM; Gutmann DH
Expert Rev Anticancer Ther; 2015 Apr; 15(4):415-23. PubMed ID: 25652347
[TBL] [Abstract][Full Text] [Related]
15. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
Prada CE; Hufnagel RB; Hummel TR; Lovell AM; Hopkin RJ; Saal HM; Schorry EK
J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602
[TBL] [Abstract][Full Text] [Related]
16. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.
Henning AM; Handrup MM; Kjeldsen SM; Larsen DA; Ejerskov C
Orphanet J Rare Dis; 2021 Nov; 16(1):489. PubMed ID: 34809690
[TBL] [Abstract][Full Text] [Related]
17. Optic pathway glioma and endocrine disorders in patients with and without NF1.
Gil Margolis M; Yackobovitz-Gavan M; Toledano H; Tenenbaum A; Cohen R; Phillip M; Shalitin S
Pediatr Res; 2023 Jan; 93(1):233-241. PubMed ID: 35538247
[TBL] [Abstract][Full Text] [Related]
18. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.
Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG
J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392
[TBL] [Abstract][Full Text] [Related]
19. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy.
Sharif S; Ferner R; Birch JM; Gillespie JE; Gattamaneni HR; Baser ME; Evans DG
J Clin Oncol; 2006 Jun; 24(16):2570-5. PubMed ID: 16735710
[TBL] [Abstract][Full Text] [Related]
20. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
